BACKGROUND: Human papillomavirus (HPV) has been reported in up to 50% of head and neck squamous cell carcinomas (HNSCCs). Presence of HPV in HNSCC has been associated with more favorable prognosis. OBJECTIVES: This study was designed to disclose HPV genotype distribution in head and neck squamous cell carcinomas (HNSCC) and their role in disease outcome. In addition, role of herpesviruses 1 and 2 (HSV-1 and -2) and cytomegalovirus (CMV) as co-factors was elucidated. STUDY DESIGN: HPV-genotyping of 106 HNSCC was done with Multimetrix(®)-kit. Luminex-based-method was used to detect HSV-1 and -2 and CMV. RESULTS: In males, 50% of HNSCC were HPV DNA positive and 25% of these were multiple HPV-types infections and in women, 72% and 31%, respectively. Low-risk (LR) HPV-types were found in 20.5% and co-infection with HSV-1 in 6.6%. Patients with HPV-positive and -negative HNSCC had similar survival. Patients not treated with chemoradiotherapy and co-infected with HSV-1 and HPV had a worse outcome. Similarly patients with LR-HPVs treated with radiotherapy had a poor prognosis. DISCUSSION: Radiotherapy for HNSCC in patients with either the presence of LR-HPV-types or a co-infection with HPV and HSV-1 may result in poor outcome.
BACKGROUND:Human papillomavirus (HPV) has been reported in up to 50% of head and neck squamous cell carcinomas (HNSCCs). Presence of HPV in HNSCC has been associated with more favorable prognosis. OBJECTIVES: This study was designed to disclose HPV genotype distribution in head and neck squamous cell carcinomas (HNSCC) and their role in disease outcome. In addition, role of herpesviruses 1 and 2 (HSV-1 and -2) and cytomegalovirus (CMV) as co-factors was elucidated. STUDY DESIGN:HPV-genotyping of 106 HNSCC was done with Multimetrix(®)-kit. Luminex-based-method was used to detect HSV-1 and -2 and CMV. RESULTS: In males, 50% of HNSCC were HPV DNA positive and 25% of these were multiple HPV-types infections and in women, 72% and 31%, respectively. Low-risk (LR) HPV-types were found in 20.5% and co-infection with HSV-1 in 6.6%. Patients with HPV-positive and -negative HNSCC had similar survival. Patients not treated with chemoradiotherapy and co-infected with HSV-1 and HPV had a worse outcome. Similarly patients with LR-HPVs treated with radiotherapy had a poor prognosis. DISCUSSION: Radiotherapy for HNSCC in patients with either the presence of LR-HPV-types or a co-infection with HPV and HSV-1 may result in poor outcome.
Authors: Heather H Nelson; Emma Contestabile; DeVon Hunter-Schlichting; Devin Koestler; Michael Pawlita; Tim Waterboer; Brock C Christensen; Curtis L Petersen; Jeffrey S Miller; Karl T Kelsey Journal: Carcinogenesis Date: 2022-06-04 Impact factor: 4.741
Authors: Anthony C Nichols; Sandeep S Dhaliwal; David A Palma; John Basmaji; Corina Chapeskie; Samuel Dowthwaite; Jason H Franklin; Kevin Fung; Keith Kwan; Brett Wehrli; Chris Howlett; Iram Siddiqui; Marina I Salvadori; Eric Winquist; Scott Ernst; Sara Kuruvilla; Nancy Read; Varagur Venkatesan; Biljana Todorovic; J Alex Hammond; James Koropatnick; Joe S Mymryk; John Yoo; John W Barrett Journal: J Otolaryngol Head Neck Surg Date: 2013-02-01